A comprehensive review of clinical trials from 2021 highlights that once-weekly subcutaneous semaglutide (1 mg) consistently lowered HbAc by 1.5 to 1.8% over 30 to 56 weeks, outperforming other medications including sitagliptin, dulaglutide, and insulin glargine in the SUSTAIN series.33 Real-world data from 2023 further support these findings, showing an average HbA1c reduction of approximately 0.9% and a fasting blood glucose decrease of 26 mg/dL after six months of once-weekly semaglutide use.34 These results underscore semaglutides ability to offer meaningful improvements in glycemic control and metabolic health for patients with T2DM
[DOI] [PubMed] [Google Scholar] 12.Tan Q., Akindehin S.E., Orsso C.E., et al
Studies comparing steady treatment to seasonal or episodic use show that continuous users maintain 70 to 85 percent of weight loss over two years, while intermittent users retain only 35 to 50 percent
207 NarenderTShwetaSTiwariPPapi ReddyKKhaliqTPrathipatiPet al
5-Amino-1MQ Protocol Formats Choose the format you are researching to see route-specific notes
Shirai, M., Hiramatsu, I., Aoki, Y., Shimoyama, H., Mizuno, T., Nozaki, T., Fukuhara, S., Iwasa, A., Kageyama, S., & Tsujimura, A
